Sat, Apr 19, 2014, 7:45 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • toowan12 toowan12 Oct 7, 2010 9:46 PM Flag

    Why mediator got it wrong,,,

    Good post. The pr reinforces your point. This ruling does not cover the validity or the infringement of the patents. Affy brought the case, as I understand, so they would not have sued or needed to sue if they stole a patent rather jnj would have sued them initially.

    I would also see Takeda (big brother) protecting it's investment and putting up a strong defense if jnj tries to unjustly rough up affy over hematide. Unlike jaggy's claim that this will be big boys trampling on little boys. JNJ knows that they will have a big player and not just small potatoes affy to contend with.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • <<This ruling does not cover the validity or the infringement of the patents. Affy brought the case, as I understand, so they would not have sued or needed to sue if they stole a patent rather jnj would have sued them initially. >>

      What has people concerned is that this does appear to be a self-inflicted wound. If this IP is in fact neither relevent to Hematide nor valid as a patent...then why bother going down this road at all, let alone proleptically? Well...there was a dispute in play, so rather than risk the costs of a full-blown lawsuit, opting for the costs of binding arbitration proceedings was clearly the better choice.

      ---I tend agree however, with the lead post of this thread...Hematide's mechanism for binding the EPO-R does not fall under the patent properties at issue, and one cannot patent a target, only a mechanism for hitting that target.

      ...anyway, the real issue is the road to approval of Hematide...which is starting to look more promising, not less.

 
AFFY
0.634-0.007(-1.09%)Apr 17 3:57 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.